Authors:
Bohm, M
Schiller, M
Nashan, D
Stadler, R
Luger, TA
Metze, D
Citation: M. Bohm et al., Diffuse melanosis arising from metastatic melanoma: Pathogenetic function of elevated melanocyte peptide growth factors, J AM ACAD D, 44(5), 2001, pp. 747-754
Authors:
August, C
Baba, HA
Heinig, J
Nashan, D
Hohn, P
Holzhausen, HJ
Metze, D
Bocker, W
Citation: C. August et al., Endometrial metastasis of a balloon cell melanoma mimicking a xanthomatousendometritis, PATHOLOGE, 22(2), 2001, pp. 145-150
Authors:
Hauschild, A
Garbe, C
Stolz, W
Ellwanger, U
Seiter, S
Dummer, R
Ugurel, S
Sebastian, G
Nashan, D
Linse, R
Achtelik, W
Mohr, P
Kaufmann, R
Fey, M
Ulrich, J
Tilgen, W
Citation: A. Hauschild et al., Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG), BR J CANC, 84(8), 2001, pp. 1036-1042
Citation: Ah. Enk et al., High dose inhalation interleukin-2 therapy for lung metastases in patientswith malignant melanoma, CANCER, 88(9), 2000, pp. 2042-2046
Authors:
Becker, J
Brocker, EB
Dummer, R
Enk, A
Garbe, C
Hauschild, A
Hein, R
Kaufmann, R
Krahn, G
Lohmann, F
Luther, H
Mauch, C
Mohr, P
Nashan, D
Neuber, K
Peter, RU
Reinhold, U
Schadendorf, D
Sebastian, G
Soyer, P
Stadler, R
Stolz, W
Tilgen, W
Trefzer, U
Tronnier, M
Ulrich, J
Volkenandt, M
Citation: J. Becker et al., Current position of the Working Group on Dermatological Oncology on high-dose therapy with interferon alpha 2b, HAUTARZT, 50(6), 1999, pp. 395-397